Subject(s)
Escherichia coli Infections , Gastroenteritis , Shiga-Toxigenic Escherichia coli , Escherichia coli Infections/diagnosis , Escherichia coli Infections/microbiology , Escherichia coli Infections/therapy , Gastroenteritis/diagnosis , Gastroenteritis/microbiology , Gastroenteritis/therapy , Humans , Male , Middle Aged , Shiga-Toxigenic Escherichia coli/isolation & purification , Tomography, X-Ray ComputedABSTRACT
OBJECTIVE: To evaluate if biomarker sampling in PCI has adhered to the 2 000 consensus document for the diagnosis of procedure-related myocardial infarction (MI). DESIGN: Firstly, a review of relevant papers from 2000 to September 2007 was done. Secondly, in October 2007, a questionnaire addressing biomarker sampling in routine PCI was sent to Danish PCI centres. RESULTS: Fourteen papers fulfilled the selection criteria. In six studies serial sampling according to the consensus document had been done. Biomarker measuring before PCI was not performed in four studies. All centres answered the questionnaire. In none of six centres the proposed 3-sample testing of biomarkers had been followed. A pre-PCI sample was taken in one centre. In approximately half of the centres biomarkers were only measured on clinical indication. CONCLUSION: Biomarker sampling for procedure-related MI according to the 2 000 consensus document has not been universally adapted. In order to avoid hampering of epidemiologic data and the comparison of future clinical trials it is proposed that the 2007 MI re-definition consensus document will be rapidly and universally accepted.